Literature DB >> 10404730

Time-course of cardiac troponin I release from isolated perfused rat hearts during hypoxia/reoxygenation and ischemia/reperfusion.

J P Bertinchant1, A Polge, E Robert, N Sabbah, P Fabbro-Peray, S Poirey, M Laprade, B Pau, J M Juan, J P Bali, J E de la Coussaye, M Dauzat.   

Abstract

The study was designed to determine the time-course of cardiac troponin I (cTn-I) release in isolated and Langendorff-perfused rat hearts during hypoxia and reoxygenation (H/Reox), and after various durations of total ischemia and subsequent reperfusion (I/R). For this purpose, in H/Reox, cTn-I was measured with the conventional Access immunoassay (ng/ml) and a new immunoassay which operates at pg/ml, and compared with creatine kinase (CK), lactate dehydrogenase (LD) and cardiac troponin T (cTn-T). In I/R, cTn-I was compared with CK and LD. The anti-Tn-I mAbs used in cTn-I assays cross-react with cTn-I of the rat. A clear difference between time-courses and concentration levels of cTn-I in I/R and H/Reox models was found. In I/R, maximum release of cTn-I, CK and LD similarly occurred within minutes following reperfusion; however cTn-I did not return to baseline values. cTn-I levels were not linked to the duration of ischemia. In I/R, we were only able to detect small cTn-I concentrations. In H/Reox experiments, cTn-I, CK and LD increased time-dependently. We found higher cTn-I maximal peak levels detected with the Access immunoassay than with the new assay (median, 0.346 ng/ml per min/g dry wt vs 132 pg/ml per min/g dry wt). cTn-T maximal concentrations were lower than maximal cTn-I levels (median, 0.117 ng/ml per min/g dry wt). Time-courses of cTn-I release were roughly similar with both assays in the H/Reox model (r = 0.90). These data indicate that the cTn-I time-course is related to experimental model (I/R or H/Reox), but also likely depends on the sensitivity of cTn-I assays in such experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404730     DOI: 10.1016/s0009-8981(99)00029-7

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

Review 1.  Perspective on the clinical application of troponin in heart failure and states of cardiac injury.

Authors:  Almasa Bass; J Herbert Patterson; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2009-04-05       Impact factor: 4.214

2.  Novel cuff design to facilitate anastomosis of small vessels during cervical heterotopic heart transplantation in rats.

Authors:  Tathyana F Fensterer; Cynthia J Miller; Gustavo Perez-Abadia; Claudio Maldonado
Journal:  Comp Med       Date:  2014-08       Impact factor: 0.982

3.  Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis.

Authors:  Jia Liu; Richard B Marchase; John C Chatham
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-06-15       Impact factor: 4.733

4.  The Coadministration of Levosimendan and Exenatide Offers a Significant Cardioprotective Effect to Isolated Rat Hearts against Ischemia/Reperfusion Injury.

Authors:  Vasileios Leivaditis; Efstratios Koletsis; Nikolaos Tsopanoglou; Nikolaos Charokopos; Cristian D'Alessandro; Konstantinos Grapatsas; Efstratios Apostolakis; Effrosyni Choleva; Maria Plota; Andreas Emmanuil; Manfred Dahm; Dimitrios Dougenis
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-12

5.  Effects of thyroid hormone analogue and a leukotrienes pathway-blocker on reperfusion injury attenuation after heart transplantation.

Authors:  Fadhil G Al-Amran; Najah R Hadi; Haider S H Al-Qassam
Journal:  ISRN Pharmacol       Date:  2013-09-17

6.  Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts.

Authors:  Vanlata Patel; Raghu Adya; Jing Chen; Manjunath Ramanjaneya; Muhammad F Bari; Sunil K Bhudia; Edward W Hillhouse; Bee K Tan; Harpal S Randeva
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.